DK2344519T3 - C-terminale fragmenter af glucagonlignende peptid-1 (glp-1) - Google Patents

C-terminale fragmenter af glucagonlignende peptid-1 (glp-1) Download PDF

Info

Publication number
DK2344519T3
DK2344519T3 DK09825560.7T DK09825560T DK2344519T3 DK 2344519 T3 DK2344519 T3 DK 2344519T3 DK 09825560 T DK09825560 T DK 09825560T DK 2344519 T3 DK2344519 T3 DK 2344519T3
Authority
DK
Denmark
Prior art keywords
obesity
glp
peptide
treatment
therapeutic composition
Prior art date
Application number
DK09825560.7T
Other languages
English (en)
Inventor
Joel F Habener
Tatsuya Yano
Eva Tomas Falco
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Application granted granted Critical
Publication of DK2344519T3 publication Critical patent/DK2344519T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Claims (10)

1. Terapeutisk sammensætning til anvendelse til behandling af obesitas eller en obesitasrelateret forstyrrelse, hvor den terapeutiske sammensætning omfatter et isoleret peptid i et fysiologisk acceptabelt bæremateriale, hvilket isolerede peptid består af sekvensen: (Phe/Tyr)-Ile-Ala-Trp-Leu-Val-(Lys/Arg)-Gly-Arg-Xaa (SEQ ID NO: 1), hvor Xaa kan være Gly, Gly-Arg, Gly-Arg-Gly eller fraværende.
2. Terapeutisk sammensætning ifølge krav 1 til anvendelse til behandling af obesitas eller en obesitasrelateret forstyrrelse, hvor peptidet er amideret, hvis C-terminalen er en Arg.
3. Terapeutisk sammensætning ifølge krav 1 til anvendelse til behandling af obesitas eller en obesitasrelateret forstyrrelse, hvor en eller flere aminosyrer er modificeret ved påhæftning af en fedtsyre.
4. Terapeutisk sammensætning ifølge krav 3 til anvendelse til behandling af obesitas eller en obesitasrelateret forstyrrelse, hvor fedtsyren er udvalgt fra gruppen, der består af palmitat og oleat.
5. Terapeutisk sammensætning ifølge krav 1 til anvendelse til behandling af obesitas eller en obesitasrelateret forstyrrelse, hvor peptidet er fusioneret til et cellepenetrerende peptid.
6. Terapeutisk sammensætning ifølge krav 5 til anvendelse til behandling af obesitas eller en obesitasrelateret forstyrrelse, hvor det cellepenetrerende peptid er fusioneret på C-terminalen af peptidet ifølge krav 1.
7. Terapeutisk sammensætning ifølge krav 5 til anvendelse til behandling af obesitas eller en obesitasrelateret forstyrrelse, hvor det cellepenetrerende peptid er udvalgt fra gruppen, der består af HIV-afledt TAT-peptid, penetratiner, transportaner, SS-peptider og hCT-afledte cellepenetrerende peptider.
8. Terapeutisk sammensætning ifølge krav 1 til anvendelse til behandling af obesitas eller en obesitasrelateret forstyrrelse, der yderligere omfatter mindst ét cellepenetrerende middel.
9. Terapeutisk sammensætning ifølge krav 8 til anvendelse til behandling af obesitas eller en obesitasrelateret forstyrrelse, hvor det cellepenetrerende middel er et kationisk liposom.
10. Terapeutisk sammensætning ifølge krav 1 til anvendelse til behandling af obesitas eller en obesitasrelateret forstyrrelse, hvor den obesitasrelaterede forstyrrelse er diabetes eller det metaboliske syndrom.
DK09825560.7T 2008-11-07 2009-11-09 C-terminale fragmenter af glucagonlignende peptid-1 (glp-1) DK2344519T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11234108P 2008-11-07 2008-11-07
US17554309P 2009-05-05 2009-05-05
US18184909P 2009-05-28 2009-05-28
PCT/US2009/063746 WO2010054326A2 (en) 2008-11-07 2009-11-09 C-terminal fragments of glucagon-like peptide-1 (glp-1)

Publications (1)

Publication Number Publication Date
DK2344519T3 true DK2344519T3 (da) 2017-01-23

Family

ID=42153626

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09825560.7T DK2344519T3 (da) 2008-11-07 2009-11-09 C-terminale fragmenter af glucagonlignende peptid-1 (glp-1)

Country Status (5)

Country Link
US (2) US8889618B2 (da)
EP (1) EP2344519B1 (da)
DK (1) DK2344519T3 (da)
ES (1) ES2614427T3 (da)
WO (1) WO2010054326A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2344519B1 (en) 2008-11-07 2016-09-28 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
WO2012061466A2 (en) * 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
EP2729157B1 (en) * 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
EP2911686B1 (en) * 2012-10-26 2021-07-28 University Health Network Peptides for preventing ischemic tissue injury
WO2014088631A1 (en) 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2016035820A1 (ja) * 2014-09-02 2016-03-10 学校法人東京理科大学 中枢作用性ペプチド誘導体及び医薬組成物
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
EP3158992A1 (en) * 2015-10-21 2017-04-26 Universität Heidelberg Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
WO2020118843A1 (zh) * 2018-12-12 2020-06-18 四川利通科创生物医药科技有限公司 一种glp-1突变体及其制备方法和用途

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
WO1999038501A2 (en) 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
WO1999053064A2 (en) 1998-04-13 1999-10-21 Modex Therapeutiques, S.A. Methods of delivering glp-1
US20030176357A1 (en) 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB9927603D0 (en) 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
ATE346093T1 (de) 2000-06-16 2006-12-15 Lilly Co Eli Analoge des glucagon ähnlichen peptid-1
WO2002010201A2 (en) 2000-07-31 2002-02-07 Active Motif Peptide-mediated delivery of molecules into cells
MXPA03005135A (es) 2000-12-13 2003-12-04 Lilly Co Eli Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
BR0206831A (pt) 2001-02-02 2004-07-06 Takeda Chemical Industries Ltd Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
WO2002085406A1 (en) 2001-04-24 2002-10-31 Restoragen, Inc. Methods and compositions for treating conditions associated with insulin resistance
MXPA04001525A (es) 2001-08-23 2004-05-31 Lilly Co Eli Analogos de peptido -1 similar al glucagon.
BR0212620A (pt) 2001-10-01 2005-09-20 Lilly Co Eli Métodos de tratamento de pacientes criticamente doentes sofrendo de angústia respiratória, e de pacientes criticamente doente possuindo uma condição que acarreta a angústia respiratória, e, uso de um composto de glp-1
CA2464995A1 (en) 2001-10-31 2003-05-08 Novartis Ag Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
WO2003045977A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
ES2545090T3 (es) * 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
CA2468700A1 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
RU2332229C2 (ru) 2002-02-20 2008-08-27 Эмисфире Текнолоджис Инк. Способ введения молекул glp-1
JP2005532283A (ja) 2002-04-08 2005-10-27 トレント・ファーマシューティカルズ・リミテッド チアゾリジン−４−カルボニトリル及び類似物ならびにジペプチジル−ペプチダーゼ阻害剤としてのそれらの使用
US7374930B2 (en) 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
US20060252916A1 (en) 2002-06-04 2006-11-09 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
ATE529126T1 (de) 2003-06-03 2011-11-15 Novo Nordisk As Stabilisierte pharmazeutische peptid zusammensetzungen
US20080194483A1 (en) 2003-12-12 2008-08-14 Brownlee Michael A GLP-1 (9-36) methods and compositions
CA2550217A1 (en) 2003-12-12 2005-07-07 Michael A. Brownlee Glp-1 (9-36) methods and compositions
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US20090202497A1 (en) 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
WO2007030706A1 (en) 2005-09-08 2007-03-15 New England Medical Center Hospitals, Inc. Fragments of the glucagon-like peptide-i and uses thereof
WO2007051987A1 (en) * 2005-11-01 2007-05-10 Activotec Spp Limited Insulinotropic compounds and uses thereof
GB0522295D0 (en) 2005-11-01 2005-12-07 Activotec Spp Ltd Peptides and uses thereof
WO2007061434A2 (en) * 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
JP2009518315A (ja) 2005-12-02 2009-05-07 エムディーアールエヌエー，インコーポレイテッド グルコース調節ペプチドの上皮透過性を増大させるための製剤処方
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
US7928186B2 (en) * 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
US8865216B2 (en) 2007-08-03 2014-10-21 National Institutes Of Health (Nih) Surface-modified nanoparticles for intracellular delivery of therapeutic agents and composition for making same
US8263347B2 (en) 2007-10-18 2012-09-11 Miyazaki Prefectural Industrial Support Foundation Biomarker for diagnosis of liver disease
WO2009074483A2 (en) * 2007-12-11 2009-06-18 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
EP2344519B1 (en) 2008-11-07 2016-09-28 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
WO2010093802A2 (en) * 2009-02-11 2010-08-19 The General Hospital Corporation Therapeutic method for increasing pancreatic beta cell mass
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
US20140212472A1 (en) 2011-07-06 2014-07-31 The General Hospital Corporation Methods of Treatment Using A Pentapeptide Derived From The C-Terminus Of Glucagon-Like Peptide 1 (GLP-1)

Also Published As

Publication number Publication date
WO2010054326A2 (en) 2010-05-14
ES2614427T3 (es) 2017-05-31
US8889618B2 (en) 2014-11-18
EP2344519A4 (en) 2012-03-14
EP2344519A2 (en) 2011-07-20
EP2344519B1 (en) 2016-09-28
US10118955B2 (en) 2018-11-06
US20110274747A1 (en) 2011-11-10
WO2010054326A3 (en) 2010-08-19
US20150133384A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
DK2344519T3 (da) C-terminale fragmenter af glucagonlignende peptid-1 (glp-1)
AU2015335828B2 (en) Co-agonists of the glucagon and GLP-1 receptors
JP5399244B2 (ja) 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
DK2440241T3 (da) Væksthormon-polypeptider og fremgangsmåder til fremstilling og anvendelse deraf
CN108026153B (zh) 作为选择性肽双重glp-1/胰高血糖素受体激动剂的新毒蜥外泌肽-4衍生物
CN107636010B (zh) 酰化胰高血糖素类似物
AU2013337250B2 (en) Long-acting single-chain insulin analogues
AU2003200839A1 (en) Extended glucagon-like peptide-1 analogs
CA3045377A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
KR20070067136A (ko) 혈관작용성 장내 폴리펩티드 제약
CA2686803A1 (en) Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
US10137171B2 (en) Methods of treatment using a pentapeptide derived from the C-Terminus of Glucagon-Like Peptide 1 (GLP-1)
RU2557301C2 (ru) Новые аналоги глюкагон-подобного пептида, композиция и способ применения
US20140212472A1 (en) Methods of Treatment Using A Pentapeptide Derived From The C-Terminus Of Glucagon-Like Peptide 1 (GLP-1)
EP4081243A1 (en) Stapled triazole co-agonists of the glucagon and glp-1 receptors
CN110023329B (en) Novel compounds as peptide triple GLP 1/glucagon/GIP receptor agonists
WO2021133643A1 (en) Stapled olefin co-agonists of the glucagon and glp-1 receptors
CA3162379A1 (en) Stapled lactam co-agonists of the glucagon and glp-1 receptors